Using the Mechanisms of Action Involved in the Pathogenesis of Androgenetic Alopecia to Treat Hair Loss.
Level 5 - mechanism / opinion, no new human data
Narrative review summarizing molecular mechanisms and therapies without systematic review methodology.
PubMed 41226747 · doi:10.3390/ijms262110712
What was done
This narrative review synthesized the pathophysiological mechanisms underlying androgenetic alopecia (AGA)—including genetic factors, androgens, growth factors, and dermal papilla-hair follicle cellular crosstalk—and reviewed pharmacological strategies targeting these pathways alongside standard FDA-approved options (topical minoxidil and oral finasteride).
What was found
The abstract reports no quantitative values, effect sizes, or study counts. It qualitatively notes that various therapies targeting AGA pathogenesis can promote hair growth and that combining certain pharmacological agents achieves better outcomes than individual monotherapies by simultaneously engaging distinct molecular pathways.
Why it matters
It highlights the mechanistic rationale for multi-target and combination drug approaches to prevent hair follicle miniaturization, potentially addressing the durability, cost, and adverse effect limitations of existing lifelong single-agent regimens.
Limits
No quantitative data, specific combination drug names, sample sizes, or study selection criteria are reported in the abstract. As a narrative review, it lacks systematic search protocols, risk-of-bias evaluation, and meta-analytic verification.
Cited by
- supports Minoxidil acts as a hair growth stimulant but does not attenuate or prevent hair follicle miniaturization caused by DHT.